Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients

1990 ◽  
Vol 26 (5) ◽  
pp. 355-358 ◽  
Author(s):  
J. P. Sculier ◽  
J. J. Body ◽  
N. Donnadieu ◽  
S. Nejai ◽  
F. Glibert ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Interleukin 2 ◽  
Bolus Administration ◽  
Advanced Cancer Patients ◽  
High Doses

Pain Control with Morphine for Vertebral Metastases and Sciatica in Advanced Cancer Patients

1994 ◽  
Vol 10 (1) ◽  
pp. 10-13 ◽  
Author(s):  
Hideo Yoshioka ◽  
Satoru Tsuneto ◽  
Tetsuo Kashiwagi
Keyword(s):  
Bone Metastases ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Bone Pain ◽  
Malignant Tumors ◽  
Spinal Metastases ◽  
Pelvic Bone ◽  
Advanced Cancer Patients ◽  
Direct Invasion ◽  
High Doses

Morphine was administered to 56 advanced cancer patients; of that number spinal metastases had induced bone pain in 28 and malignant tumors had induced sciatica in 28. The sciatica was caused in 16 patients by direct invasion of the sacral plexus, in four by lumbar bone metastases, and in eight by pelvic bone metastases. Spinal bone pain was controlled adequately with morphine. However, sciatica required larger dosages of morphine than did bone pain. Among the group with sciatica, rectal cancer patients needed larger dosages of morphine than the other cancer patients. Even with high doses of morphine, it was occasionally difficult to control neuropathic pain of the sciatic nerve caused by intrapelvic cancer.

A Phase IA/IB Trial of Anti-CD3 Murine Monoclonal Antibody plus Low-Dose Continuous-Infusion Interleukin-2 in Advanced Cancer Patients

1995 ◽  
Vol 17 (2) ◽  
pp. 171-180 ◽  
Author(s):  
Jeffrey A. Sosman ◽  
Catherine Kefer ◽  
Richard I. Fisher ◽  
Cheryl D. Jacobs ◽  
Peggy Pumfery ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Continuous Infusion ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Low Dose ◽  
Interleukin 2 ◽  
Murine Monoclonal Antibody ◽  
Advanced Cancer Patients

scholarly journals Antitumor Effects of Selenium

2021 ◽  
Vol 22 (21) ◽  
pp. 11844
Author(s):  
Seung Jo Kim ◽  
Min Chul Choi ◽  
Jong Min Park ◽  
An Sik Chung
Keyword(s):  
Radiation Therapy ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Sodium Selenite ◽  
Subsequent Treatment ◽  
Advanced Cancer Patients ◽  
Antitumor Effects ◽  
Hydrogen Selenide ◽  
High Doses

Functions of selenium are diverse as antioxidant, anti-inflammation, increased immunity, reduced cancer incidence, blocking tumor invasion and metastasis, and further clinical application as treatment with radiation and chemotherapy. These functions of selenium are mostly related to oxidation and reduction mechanisms of selenium metabolites. Hydrogen selenide from selenite, and methylselenol (MSeH) from Se-methylselenocyteine (MSeC) and methylseleninicacid (MSeA) are the most reactive metabolites produced reactive oxygen species (ROS); furthermore, these metabolites may involve in oxidizing sulfhydryl groups, including glutathione. Selenite also reacted with glutathione and produces hydrogen selenide via selenodiglutathione (SeDG), which induces cytotoxicity as cell apoptosis, ROS production, DNA damage, and adenosine-methionine methylation in the cellular nucleus. However, a more pronounced effect was shown in the subsequent treatment of sodium selenite with chemotherapy and radiation therapy. High doses of sodium selenite were effective to increase radiation therapy and chemotherapy, and further to reduce radiation side effects and drug resistance. In our study, advanced cancer patients can tolerate until 5000 μg of sodium selenite in combination with radiation and chemotherapy since the half-life of sodium selenite may be relatively short, and, further, selenium may accumulates more in cancer cells than that of normal cells, which may be toxic to the cancer cells. Further clinical studies of high amount sodium selenite are required to treat advanced cancer patients.

Clinical and Immunological Studies in Advanced Cancer Patients Sequentially Treated with Anti CD3 Monoclonal Antibody (OKT3) and Interleukin-2

1996 ◽  
Vol 21 (3-4) ◽  
pp. 325-330 ◽  
Author(s):  
Paolo Borrione ◽  
Laura Montacchini ◽  
Eloise Beggiato ◽  
Alessandro Pileri ◽  
Alberto Bianchi ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Interleukin 2 ◽  
Advanced Cancer Patients

scholarly journals A Personalized short-time Immunotherapy with Subcutaneous very low-dose Il-2 plus the Pineal Hormone Melatonin in advanced cancer patients with Persistent Lymphocytopenia

2020 ◽  
pp. 01-07
Author(s):  
Paolo Lissoni ◽  
Giusy Messina ◽  
Andrea Sassola ◽  
Giorgio Porro ◽  
Simonetta Tassoni ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Lymphocyte Count ◽  
Low Dose ◽  
Prognostic Significance ◽  
Interleukin 2 ◽  
Palliative Therapy ◽  
Advanced Cancer Patients ◽  
Genetic Characteristics ◽  
Mean Values

Today, it is known that the prognosis of human neoplasms depends not only on the genetic characteristics of tumor cells, but also on the immunobiological response of patients. Moreover, despite its complexity, at present it is known that the antitumor immunity is generally suppressed by the macrophage system, and stimulated by T lymphocytes, with the only exception of regulatory T cells, which in contrast inhibit the anticancer immunity through the release of immunosuppressive cytokines, the most important of them is TGF-beta. Finally, it is known that lymphocytopenia may predict a negative prognosis in the advanced neoplasms, and a more negative significance is played by the occurrence of abnormally low values of lymphocyte-to-monocyte ratio (LMR), whose decline could depend on both lymphocyte decrease and monocyte increase. At present, the only cytokine able to enhance lymphocyte count still remains IL-2. Therefore, because of the negative prognostic significance of cancer-related lymphocytopenia, the use of IL-2 to correct cancer-related lymphocytopenia could constitute a new strategy in the immunotherapy of cancer. On these bases, a study was planned to evaluate the effects of a neuro-immunotherapeutic combination with SC very-low dose IL-2 in association with the antitumor immunostimulating pineal hormone melatonin (MLT) on lymphocyte count, and their persistence on time in a group of untreatable lymphocytopenic advanced cancer patients. The study included 14 lymphocytopenic cancer patients, who were eligible for the only palliative therapy. IL-2 was SC injected at 1.8 MIU/day for 5 days/week for 2 consecutive weeks, in association with MLT at 100 mg/day orally during the dark period of the day. A normalization of lymphocyte count was achieved in 9/14 (64%) patients within the two weeks of therapy. Both lymphocyte and LMR mean values significantly increased on therapy with respect to the pre-treatment values. On the other hand, monocyte mean values diminished on therapy, without, however, significant differences. The median duration of lymphocyte count normalization was 160 days (range 39-240 days). These preliminary results would suggest a new possible clinical use of IL-2 immunotherapy to counteract advanced cancer-related lymphocytopenia, because of its well documented negative effects on the survival, in an attempt to control tumor growth by activating the natural antitumor immunobiological response, which is fundamentally an IL-2-dependent phenomenon, and which is altered in the advanced human neoplasms. Keywords: Cancer immunotherapy, Interleukin-2, Lymphocytopenia, Immunosuppression, Melatonin, Pineal gland

Lifestyle Interference And Emotional Distress In Family Caregivers Of Advanced Cancer Patients

2002 ◽  
Author(s):  
Jill I. Cameron ◽  
Renee-Louise Tranche ◽  
Angela M. Cheung ◽  
Donna E. Stewart
Keyword(s):  
Cancer Patients ◽  
Family Caregivers ◽  
Advanced Cancer ◽  
Emotional Distress ◽  
Advanced Cancer Patients

The Cachexia Clinic: From Staging to Managing Nutritional and Functional Problems in Advanced Cancer Patients

2012 ◽  
Vol 17 (3) ◽  
pp. 293-304 ◽  
Author(s):  
Antonio Vigano ◽  
Egidio Del Fabbro ◽  
Eduardo Bruera ◽  
Manuel Borod
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Advanced Cancer Patients ◽  
Functional Problems
Sign in / Sign up

Export Citation Format

Share Document